Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial

Article ID	Journal	Published Year	Pages	File Type
8721683	Diabetes & Metabolism	2017	7 Pages	PDF

Abstract

The ODYSSEY DM-INSULIN study will provide information on the efficacy and safety of alirocumab in insulin-treated individuals with T1 or T2 DM who are at high CV risk and have hypercholesterolaemia not adequately controlled by the maximum tolerated statin therapy.

Keywords

LDL particle every 2 weeks PCSK9 LLT LDL-P CHD Odyssey HDL-C MMRM LDL-C Q2W ASCVD Lp(a)mITT Myocardial infarction unstable angina apo apolipoprotein modified intention-to-treat insulin ITT Peripheral arterial disease coronary heart disease cardiovascular disease Atherosclerotic cardiovascular disease Diabetes triglyceride Diabetes mellitus CVD adverse event Alirocumab intention-to-treat cardiovascular Lipoprotein(a)high-density lipoprotein cholesterol Type 1 Type 2 PAD Proprotein convertase subtilisin/kexin type 9 Lipid-lowering therapy Low-density lipoprotein cholesterol

Related Topics

Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism

Preview

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial

Authors

B. Cariou, L.A. Leiter, D. Müller-Wieland, G. Bigot, H.M. Colhoun, S. Del Prato, R.R. Henry, F.J. Tinahones, A. Letierce, L. Aurand, J. Maroni, K.K. Ray, M. Bujas-Bobanovic,